来自哪里的研究人员开展的一项回顾性研究，针对骨优势型转移性去势抵抗性前列腺癌（mCRPC）患者，探索[1??Lu]Lu-PSMA-617治疗中Ga-68 PSMA PET/CT体积参数的预后价值。研究发现，中期扫描中新病灶的出现和骨病灶体积减少≤10.7%可独立预测较短的PSA无进展生存（PSA-PFS ...

前列腺癌PSMA探针[68Ga]Ga-P16-093的诊断效能及局部分期价值评估。前瞻性研究纳入56例初诊前列腺癌患者，比较其与[68Ga]Ga-PSMA-11显像的SUVmax（9.86±6.82 vs 6.74±1.89）、AUC（0.85 vs 0.75）及局部分期准确率（59.46% vs 32.43%），证实P16-093在原发肿瘤诊断和局部分期方面更具 ...

Getty Images Ga 68 PSMA-11 PET can detect sites of local recurrence or metastasis in patients with biochemical evidence of recurrent prostate cancer. The FDA has approved gallium 68 PSMA-11 (Ga 68 ...

Detection of prostate cancer and its recurrence is challenging as it is a heterogeneous disease and methods such as PET imaging and measurement of biochemical response using prostate specific membrane ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

A recent study reported in The Journal of Nuclear Medicine compared use of the novel Ga-68-PSMA-ligand PET/CT with other imaging methods and found that it had substantially higher detection rates of ...

Functional outcome and quality of life in patients undergoing salvage radical prostatectomy (SRPE). This is an ASCO Meeting Abstract from the 2018 Genitourinary Cancers Symposium. This abstract does ...

Randomized phase II trial of docetaxel plus prednisolone with or without androgen deprivation treatment in castration-resistant prostate cancer. This is an ASCO Meeting Abstract from the 2016 ...

As the only diagnostic agent for suspected metastatic and recurrent prostate cancer that combines the accuracy of gallium imaging with the reliability and flexibility of Telix's distribution network, ...